Two nuclear factor binding domains activate expression from the human amyloid beta-protein precursor promoter

Area of Science:

• Neuroscience
• Molecular Biology
• Genetics

Background:

• Amyloid beta-protein, a key component of brain amyloid depositions in Alzheimer's disease and Down's syndrome, originates from the amyloid precursor protein (APP).
• Overexpression of APP is a potential factor in amyloid formation, necessitating an understanding of its gene regulation.

Purpose of the Study:

• To investigate the regulatory mechanisms governing human APP gene expression.
• To identify and characterize the functional roles of specific nuclear factor binding domains within the APP promoter.

Main Methods:

• Analysis of the human APP promoter region, focusing on 94 base pairs upstream of the transcriptional start site.
• Identification of two nuclear factor binding domains: APB alpha and APB beta.
• Transient transfection assays in HeLa and PC-12 cells to assess promoter activity.

Main Results:

• The APB beta binding domain (GCCGCTAGGGGT, -93 to -82) accounts for 70-90% of the total APP promoter activity under standard conditions.
• The APB alpha binding domain (GGATCAGCTGAC, -53 to -42) contributes 10-30% to APP promoter activity.
• Elimination of both APB alpha and APB beta binding sites significantly reduces APP promoter activity to near background levels.

Conclusions:

• The human APP promoter activity is primarily driven by the APB beta binding domain, with a lesser contribution from APB alpha.
• Both identified binding domains are crucial for maintaining basal APP gene expression.
• These findings provide insight into the transcriptional regulation of APP, relevant to understanding Alzheimer's disease and Down's syndrome.